BACKGROUND: The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas. However, a comprehensive assessment of biologic pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction has not been performed. METHODS: We conducted aptamer-based proteomic analysis utilizing 5284 modified aptamers to 4928 unique proteins on plasma samples from TOPCAT participants from the Americas (n=164 subjects with paired samples at baseline and 1 year) to identify proteins and pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction. Mean percentage change from baseline was calculated for each protein. Additionally, we conducted pathway analysis of proteins altered by spironolactone. RESULTS: Spironolactone therapy was associated with proteome-wide significant changes in 7 proteins. Among these, CARD18 (caspase recruitment domain-containing protein 18), PKD2 (polycystin 2), and PSG2 (pregnancy-specific glycoprotein 2) were upregulated, whereas HGF (hepatic growth factor), PLTP (phospholipid transfer protein), IGF2R (insulin growth factor 2 receptor), and SWP70 (switch-associated protein 70) were downregulated. CARD18, a caspase-1 inhibitor, was the most upregulated protein by spironolactone (-0.5% with placebo versus +66.5% with spironolactone, P<0.0001). The top canonical pathways that were significantly associated with spironolactone were apelin signaling, stellate cell activation, glycoprotein 6 signaling, atherosclerosis signaling, liver X receptor activation, and farnesoid X receptor activation. Among the top pathways, collagens were a consistent theme that increased in patients receiving placebo but decreased in patients randomized to spironolactone. CONCLUSIONS: Proteomic analysis in the TOPCAT trial revealed proteins and pathways altered by spironolactone, including the caspase inhibitor CARD18 and multiple pathways that involved collagens. In addition to effects on fibrosis, our studies suggest potential antiapoptotic effects of spironolactone in heart failure with preserved ejection fraction, a hypothesis that merits further exploration.
BACKGROUND: The TOPCAT trial (Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist Trial) suggested clinical benefits of spironolactone treatment among patients with heart failure with preserved ejection fraction enrolled in the Americas. However, a comprehensive assessment of biologic pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction has not been performed. METHODS: We conducted aptamer-based proteomic analysis utilizing 5284 modified aptamers to 4928 unique proteins on plasma samples from TOPCAT participants from the Americas (n=164 subjects with paired samples at baseline and 1 year) to identify proteins and pathways impacted by spironolactone therapy in heart failure with preserved ejection fraction. Mean percentage change from baseline was calculated for each protein. Additionally, we conducted pathway analysis of proteins altered by spironolactone. RESULTS: Spironolactone therapy was associated with proteome-wide significant changes in 7 proteins. Among these, CARD18 (caspase recruitment domain-containing protein 18), PKD2 (polycystin 2), and PSG2 (pregnancy-specific glycoprotein 2) were upregulated, whereas HGF (hepatic growth factor), PLTP (phospholipid transfer protein), IGF2R (insulin growth factor 2 receptor), and SWP70 (switch-associated protein 70) were downregulated. CARD18, a caspase-1 inhibitor, was the most upregulated protein by spironolactone (-0.5% with placebo versus +66.5% with spironolactone, P<0.0001). The top canonical pathways that were significantly associated with spironolactone were apelin signaling, stellate cell activation, glycoprotein 6 signaling, atherosclerosis signaling, liver X receptor activation, and farnesoid X receptor activation. Among the top pathways, collagens were a consistent theme that increased in patients receiving placebo but decreased in patients randomized to spironolactone. CONCLUSIONS: Proteomic analysis in the TOPCAT trial revealed proteins and pathways altered by spironolactone, including the caspase inhibitor CARD18 and multiple pathways that involved collagens. In addition to effects on fibrosis, our studies suggest potential antiapoptotic effects of spironolactone in heart failure with preserved ejection fraction, a hypothesis that merits further exploration.
Authors: Senthil Selvaraj; Brian Claggett; Sanjiv J Shah; Inder Anand; Jean L Rouleau; Akshay S Desai; Eldrin F Lewis; Bertram Pitt; Nancy K Sweitzer; Marc A Pfeffer; Scott D Solomon Journal: Eur J Heart Fail Date: 2017-11-16 Impact factor: 15.534
Authors: Bertram Pitt; Marc A Pfeffer; Susan F Assmann; Robin Boineau; Inder S Anand; Brian Claggett; Nadine Clausell; Akshay S Desai; Rafael Diaz; Jerome L Fleg; Ivan Gordeev; Brian Harty; John F Heitner; Christopher T Kenwood; Eldrin F Lewis; Eileen O'Meara; Jeffrey L Probstfield; Tamaz Shaburishvili; Sanjiv J Shah; Scott D Solomon; Nancy K Sweitzer; Song Yang; Sonja M McKinlay Journal: N Engl J Med Date: 2014-04-10 Impact factor: 91.245
Authors: Wojciech Kosmala; Monika Przewlocka-Kosmala; Hanna Szczepanik-Osadnik; Andrzej Mysiak; Trisha O'Moore-Sullivan; Thomas H Marwick Journal: JACC Cardiovasc Imaging Date: 2011-12
Authors: Egil Ferkingstad; Patrick Sulem; Bjarni A Atlason; Gardar Sveinbjornsson; Magnus I Magnusson; Edda L Styrmisdottir; Kristbjorg Gunnarsdottir; Agnar Helgason; Asmundur Oddsson; Bjarni V Halldorsson; Brynjar O Jensson; Florian Zink; Gisli H Halldorsson; Gisli Masson; Gudny A Arnadottir; Hildigunnur Katrinardottir; Kristinn Juliusson; Magnus K Magnusson; Olafur Th Magnusson; Run Fridriksdottir; Saedis Saevarsdottir; Sigurjon A Gudjonsson; Simon N Stacey; Solvi Rognvaldsson; Thjodbjorg Eiriksdottir; Thorunn A Olafsdottir; Valgerdur Steinthorsdottir; Vinicius Tragante; Magnus O Ulfarsson; Hreinn Stefansson; Ingileif Jonsdottir; Hilma Holm; Thorunn Rafnar; Pall Melsted; Jona Saemundsdottir; Gudmundur L Norddahl; Sigrun H Lund; Daniel F Gudbjartsson; Unnur Thorsteinsdottir; Kari Stefansson Journal: Nat Genet Date: 2021-12-02 Impact factor: 38.330
Authors: Luigi Adamo; Jinsheng Yu; Cibele Rocha-Resende; Ali Javaheri; Richard D Head; Douglas L Mann Journal: J Am Coll Cardiol Date: 2020-10-27 Impact factor: 24.094
Authors: João Pedro Ferreira; Job Verdonschot; Ping Wang; Anne Pizard; Timothy Collier; Fozia Z Ahmed; Hans-Peter Brunner-La-Rocca; Andrew L Clark; Franco Cosmi; Joe Cuthbert; Javier Díez; Frank Edelmann; Nicolas Girerd; Arantxa González; Stéphanie Grojean; Mark Hazebroek; Javed Khan; Roberto Latini; Mamas A Mamas; Beatrice Mariottoni; Blerim Mujaj; Pierpaolo Pellicori; Johannes Petutschnigg; Burkert Pieske; Patrick Rossignol; Philippe Rouet; Jan A Staessen; John G F Cleland; Stephane Heymans; Faiez Zannad Journal: JACC Heart Fail Date: 2021-02-03 Impact factor: 12.035